Trial Profile
A Pilot Study of Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin (SCCS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Skin cancer; Squamous cell cancer
- Focus Therapeutic Use
- 30 Nov 2023 Status changed from active, no longer recruiting to completed.
- 13 Apr 2023 Planned End Date changed from 1 Dec 2022 to 30 Dec 2024.
- 13 Apr 2023 Planned primary completion date changed from 1 Dec 2022 to 30 Dec 2023.